Plus Therapeutics, Inc. PSTV
Set alert
At close · Jul 31
After hours · Jul 31, 4:00 PM ET
- YTD
- -69.65%
- 1 year
- -58.16%
- Open
- 3.65
- Prev close
- 3.87
- Mkt cap
- 6.31M
- Vol
- 96.53K
- Avg vol
- 92.10K
- EPS
- -2.37
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 3.62
- High
- 3.94
- Forward P/E
- -0.52
- Beta
- 0.69
- Short ratio
- 0.98
- Inst. own
- 11.39%
- Dividend
- 0.00
- Ex-div date
- 50-d avg
- 1.29
- 200-d avg
- 1.63
- 1y target
- 15.75
Key statistics
- Market cap
- 6.31M
- Enterprise value
- 1.90M
- Trailing P/E
- 0.00
- Forward P/E
- -0.52
- PEG ratio
- 0.00
- Price / sales
- 1.15
- Price / book
- 0.00
- EPS (TTM)
- -2.37
- Beta
- 0.69
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Profit margin
- -240.15%
- Revenue (TTM)
- 5.51M
- Revenue growth
- -31.00%
- Free cash flow
- -1.10M
- Total cash
- 8.44M
- Total debt
- 3.43M
- Return on equity
- 0.00%
- Shares outstanding
- 5.90M
- Short % of float
- 0.90%
- 50-day average
- 1.29
- 200-day average
- 1.63
Analyst view
Consensus: none
- Target (low)
- 4.00
- Target (mean)
- 15.75
- Target (high)
- 32.00
- Strong buy2
- Buy2
- Hold0
- Sell0
- Strong sell0
Next earnings
Consensus EPS estimate -0.5125.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 14, 2024 | Sep 1, 2024 | -0.46 | -0.46 | 0.00 | 0.00% |
| Aug 14, 2024 | Jun 1, 2024 | 0.00 | -0.71 | — | — |
| May 15, 2024 | Mar 1, 2024 | 0.00 | -0.75 | — | — |
| Mar 5, 2024 | Dec 1, 2023 | -0.78 | -0.70 | +0.08 | +10.26% |
| Oct 31, 2023 | Sep 1, 2023 | -0.58 | -1.00 | -0.42 | -72.41% |
| Aug 14, 2023 | Jun 1, 2023 | -1.91 | -0.59 | +1.32 | +69.11% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Dec 9, 2024 | Ascendiant Capital | main | Buy | Buy |
| Nov 26, 2024 | HC Wainwright & Co. | reit | Buy | Buy |
| Nov 15, 2024 | HC Wainwright & Co. | reit | Buy | Buy |
| Aug 16, 2024 | HC Wainwright & Co. | reit | Buy | Buy |
| Aug 15, 2023 | HC Wainwright & Co. | reit | Buy | Buy |
| Aug 14, 2023 | HC Wainwright & Co. | reit | Buy | Buy |
About Plus Therapeutics, Inc.
Plus Therapeutics, Inc., a clinical-stage pharmaceutical company, focuses on the development, manufacture, and commercialization of treatments for patients with cancer. Its lead radiotherapeutic drug candidate is rhenium (186Re) obisbemeda, a patented radiotherapy that targets central nervous system cancers and other cancers, including recurrent glioblastoma, leptomeningeal metastases, and pediatric brain cancers. The company also develops Rhenium-188 NanoLiposome Biodegradable Alginate Microsphere that is designed to treat various solid organ cancers comprising primary and secondary liver cancers by intra-arterial injection. It has license agreements with NanoTx, Corp. and The University of Texas Health Science Center at San Antonio. The company was formerly known as Cytori Therapeutics, Inc. and changed its name to Plus Therapeutics, Inc. in July 2019. Plus Therapeutics, Inc. was founded in 1996 and is headquartered in Austin, Texas.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- plustherapeutics.com
News
- Cerenome Announces Up to $20 Million Financing Facility with Royalty-Based Repayment
- Cerenome Highlights Presentations at the 2026 SNO/ASCO CNS Metastases Conference Demonstrating Progress in Both Therapeutics and Diagnostics Business Lines
- Cerenome Reports Second Quarter 2026 Financial Results and Business Update
- Cerenome Secures In-Network Agreement with Health Care Service Corporation, Expanding CNSide® Contracted Coverage to Over 150 Million Covered Lives
- Plus Therapeutics, Inc. (NASDAQ:PSTV) Receives Consensus Recommendation of “Hold” from Brokerages
- Cerenome Launches as an Integrated CNS Oncology Company
- Plus Therapeutics Announces Scientific Presentations and Sponsored Symposium at 2026 SNO/ASCO CNS Metastases Conference
- Plus Therapeutics Secures Regional Coverage Agreement with Medical Mutual for CNSide® Cerebrospinal Fluid Assay for Metastatic CNS Cancer
- Plus Therapeutics and Genomic Testing Cooperative Partner to Integrate Next-Generation Sequencing Into the CNSide® CSF Assay Platform
- Plus Therapeutics Highlights NCCN CNS Cancers Guidelines Update and Reinforces Clinical Role of CNSide® in Leptomeningeal Metastases Monitoring
Your note
Sign in to keep a note on PSTV — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| CLOWES HOWARD | Director | Purchase | Sep 10, 2024 | 26,497 |
| HAWKINS RICHARD JAMES | Director | Purchase | Sep 12, 2024 | 0 |
| HEDRICK MARC HAMILTON | Chief Executive Officer | Purchase | Sep 9, 2024 | 20,425 |
| LENK ROBERT P | Director | Purchase | May 7, 2024 | 29,327 |
| PETERSEN GREG B | Director | Purchase | Sep 10, 2024 | 48,921 |
| SIMS ANDREW JOHN HUGH MACINTYRE | Chief Financial Officer | Purchase | Sep 9, 2024 | 9,815 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| AIGH Capital Management LLC | 9.51% | 560,905 | 600.17K | Sep 29, 2024 |
| Geode Capital Management, LLC | 0.92% | 54,274 | 58.07K | Sep 29, 2024 |
| Vanguard Group Inc | 0.55% | 32,541 | 34.82K | Sep 29, 2024 |
| Ashton Thomas Private Wealth, LLC | 0.22% | 12,913 | 13.82K | Sep 29, 2024 |
| Blackrock Inc. | 0.12% | 6,960 | 7.45K | Sep 29, 2024 |
| Tower Research Capital LLC (TRC) | 0.06% | 3,709 | 3.97K | Sep 29, 2024 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Fidelity Extended Market Index Fund | 0.60% | 35,470 | 37.95K | Oct 30, 2024 |
| Vanguard Extended Market Index Fund | 0.55% | 32,541 | 34.82K | Sep 29, 2024 |
| Fidelity NASDAQ Composite Index Fund | 0.15% | 8,899 | 9.52K | Oct 30, 2024 |
| Fidelity Series Total Market Index Fund | 0.14% | 8,280 | 8.86K | Oct 30, 2024 |
| Fidelity Total Market Index Fund | 0.09% | 5,315 | 5.69K | Oct 30, 2024 |